Atherosclerotic cardiovascular events associated with immune checkpoint inhibitors in cancer patients
- 28 March 2022
- journal article
- review article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 52 (7) , 659-664
Abstract
Immune checkpoint inhibitors have demonstrated significant clinical benefits in many cancers, and the use of these drugs is rapidly expanding. Unfortunately, these agents can induce a wide range of immune-related adverse events through the activation of immune responses in non-target organs, including the cardiovascular system. Among cardiovascular immune-related adverse events, myocarditis is the most established and biologically plausible cardiac complication of immune checkpoint inhibitors therapy with immune-related pathophysiology. In contrast, atherosclerotic cardiovascular diseases, such as myocardial infarction and ischemic stroke, were not previously recognized as a part of the immune-related adverse event spectrum. However, there is now increasing preclinical and clinical evidence that suggests a possible correlation between immune checkpoint inhibitors therapy and atherosclerotic cardiovascular events, and cardiovascular disease is increasingly recognized as a toxicity of ICIs. Results from animal studies suggest that the blockade of the cytotoxic T-lymphocyte antigen 4 or programmed cell death protein 1 pathway plays a relevant role in promoting the progression of atherosclerotic lesions. Several clinical studies have reported an increased incidence of atherosclerotic vascular events after immune checkpoint inhibitor administration. Our findings suggest that clinicians should (i) recognize that immune checkpoint inhibitors can exacerbate atherosclerosis, (ii) consider the management of cardiovascular risk factors and (iii) perform periodic screening in patients receiving immune checkpoint inhibitors.Keywords
Funding Information
- Japan Society for the Promotion of Science (20K08396)
This publication has 32 references indexed in Scilit:
- Overexpression of Cytotoxic T-Lymphocyte–Associated Antigen-4 Prevents Atherosclerosis in MiceArteriosclerosis, Thrombosis, and Vascular Biology, 2016
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combinationNature Reviews Clinical Oncology, 2016
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paperAnnals of Oncology, 2015
- Molecular and cellular insights into T cell exhaustionNature Reviews Immunology, 2015
- A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitorsAnnals of Oncology, 2015
- Programmed Cell Death-1 Deficiency Exacerbates T Cell Activation and Atherogenesis despite Expansion of Regulatory T Cells in Atherosclerosis-Prone MicePLOS ONE, 2014
- Impairment of the Programmed Cell Death-1 Pathway Increases Atherosclerotic Lesion Development and InflammationArteriosclerosis, Thrombosis, and Vascular Biology, 2011
- Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in miceJournal of Clinical Investigation, 2007
- PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progressionNature, 2006
- Inflammation in atherosclerosisNature, 2002